Survival in childhood cancer has improved to approximately
80% in high-income countries (HIC) [1]. This success story is
attributable to advances in diagnosis and risk stratification,
and the protocolized administration of cytotoxic therapy
[1,2]. However, the survival lags by 50% in low-income and
low-and middle-income countries (LMIC) [1]. The road blocks
faced by children with cancer in LMIC include resource
constraints, a delayed presentation with advanced disease,
treatment abandonment, malnutrition, and increased
treatment-related toxicity. Treatment protocols that have been
established and validated in HIC are not designed to address
the challenges prevalent in LMICs [2]. Malignancy accounts for
approximately 1% of deaths in children aged 5-14 years in
India [3]. Novel Cost-effective strategies to treat children
with cancer are of immense importance in LMICs such as India.
Conventionally, oncological trials have focused on the
eradication of the malignancy and the reduction of relapse.
With the best of infrastructure, a realistic possibility of a
cure in every child with cancer is not conceivable. Five-year
overall survival reported in high-risk malignancies such as
acute myeloid leukamia, soft tissue/bone sarcomas and
neuroblastoma; is markedly lesser when compared to
malignancies such as Hodgkin lymphoma, Wilms tumor and germ
cell tumors [4]. Survival is notably inferior in metastatic
cancers and cancers that are refractory to therapy, or relapse
following completion of therapy. Salvage treatment for such
cancers is resource-intensive and toxic, and therefore often
impractical in LMICs [5].
Metronomic therapy is an alternative paradigm in the
management of children with cancer [5]. The approach involves
the prolonged administration of chemo-therapeutic agents in
low, minimally toxic doses with no prolonged drug-free breaks
[6]. Further, repurposed non-cytotoxic drugs, e.g.
celecoxib, thalidomide and valproate, are incorporated into
metronomic protocols [7]. In comparison, standard chemotherapy
regimens utilize maximally tolerated doses (MTD) of cytotoxic
drugs administered over a definite time [6]. Chemotherapy at
MTD directly targets the cancer cells, which have an inherent
tendency to develop mechanisms of resistance (akin to bacteria
treated with antibiotics) [8]. Therapy at MTD necessitates
breaks to allow recovery from toxicity, which further
facilitates tumor cell proliferation [6]. Alternatively,
metronomic therapy attempts to collapse the house by breaking
the scaffold. That is, it targets the endothelial cells in the
tumor microenvironment by anti-angiogenic mechanisms [6,8].
Additionally, metronomic therapy attempts to switch on the
natural immune surveillance mechanisms against the malignant
clone and induce tumor cell dormancy [6,8]. The prolonged oral
maintenance therapy in acute lymphoblastic leukemia and the
recent evidence favoring maintenance therapy in high-risk
rhabdomyo-sarcoma stand testimony to the impact of a
metronomic approach on outcome in pediatric malignancies
[9,10]. Web Table I
lists recent Indian studies which have demonstrated the
feasibility and utility of metronomic therapy in children with
high-risk cancers. Low cost, minimal toxicity, home-based
intake of oral drugs, and a reduction in the need to travel to
the hospital and admission comprise the self-evident benefits
of metronomic therapy in LMICs [5,6].
Although metronomic therapy appears
simple and attractive, there are caveats which need to be
addressed. Standard chemotherapy regimens are ratified by
randomized trials. Phase III trials, response criteria such as
radiological remission in solid malignancies and lymphomas,
minimal residual disease assessment in leukemia and outcomes
such as disease-free survival may not be relevant in patients
on a metronomic regimen [5,11]. Pharmacokinetic studies to
optimize drug doses, identification of beneficiary disease
subgroups and biological markers for response assessment
constitute areas that merit research in the metronomic field
[11]. This issue of Indian Pediatrics carries an
important study in this regard. Pramanik, et al. [12]
performed a placebo-controlled randomized trial of metronomic
therapy in children with progressive extracranial solid
malignancies. The clinical aspects of the study were published
previously and are briefly described in
Web Table I [12]. The current study evaluated
specific biomarkers in the same patient cohort. The authors
examined the baseline and subsequent levels of vascular
endothelial growth factor (VEGF) a
pro-angiogenic cytokine, and thrombospondin-1 (TSP-1),
an anti-angiogenic cytokine [13]. Although the study concluded
that these were not reliable biomarkers for assessment of
response to metronomic chemotherapy, some interesting trends
were illustrated. The baseline VEGF levels were lower in
responders. TSP-1 decreased in responders and increased in
non-responders in the metronomic arm.A similar finding was not
observed in the placebo arm. The results reaffirm the
influence of metronomic treatment on angiogenesis. The study
opens new vistas for research in metronomics. For instance,
biomarkers such as VEGF levels may show promise as surrogates
for identifying patients who would benefit with a metronomic
approach. Since the effects of metronomic therapy encompass
multiple pathways, the authors rightly state in their
discussion that a broader spectrum of circulating biomarkers
needs to be studied to yield clinically relevant indicators
[13].
A survey of pediatric oncology
physicians working in LMIC revealed a strong belief that the
use of metronomic therapy is likely to increase with time
[14]. An overwhelming majority expressed interest to
participate in international studies and registries [14].
Research in metronomic therapy can fill many lacunae, if not
all, in the treatment armamentarium for children with cancer.
Competing interests:
None stated; Funding: None.
REFERENCES
1. Lam CG, Howard SC,
Bouffet E, Pritchard-Jones K. Science and health for all
children with cancer. Science. 2019;363:1182-6.
2. Howard SC, Davidson A,
Luna-Fineman S, Israels T, Chantada G, Lam CG, et al. A
framework to develop adapted treatment regimens to manage
pediatric cancer in low-and middle-income countries: The
Pediatric Oncology in Developing Countries (PODC) Committee of
the International Pediatric Oncology Society (SIOP). Pediatr
Blood Cancer. 2017;64.
3. Causes of Death Statistics. Census of India Website.
Available from:
http://censusindia.gov.in/vital_statistics/causesofdeath.html.
Accessed March 3, 2020.
4. Arora RS, Eden TOB,
Kapoor G. Epidemiology of child-hood cancer in India. Indian J
Cancer. 2009;46:264-73.
5. André N,
Banavali S, Snihur Y, Pasquier E. Has the time come for
metronomics in low-income and middle-income countries? Lancet
Oncol. 2013;14:e239-48.
6. André N, Banavali S,
Fousseyni T, Pasquier E. Metronomic chemotherapy in pediatric
oncology: A way forward for low-income countries? In:
Oncopedia. St. Jude Cure4Kids: An International Medical
Education Website and
Online Collaboration Center. Available from:
https://www.cure4kids.org/.Accessed February 23, 2020.
7. Rumore MM. Medication
repurposing in pediatric patients: Teaching old drugs new
tricks. J Pediatr Pharmacol Ther. 2016;21:36-53.
8. Kareva I, Waxman DJ,
Lakka Klement G. Metronomic chemotherapy: An attractive
alternative to maximum tolerated dose therapy that can
activate anti-tumor immunity and minimize therapeutic
resistance. Cancer Lett. 2015;358:100-6.
9. Andre N, Cointe S,
Barlogis V, Arnaud L,
Lacroix R, Pasquier E, et al. Maintenance
chemotherapy in children with ALL exerts metronomic-like
thrombospondin-1 associated anti-endothelial effect.
Oncotarget. 2015;6: 23008-14.
10. Bisogno G, De Salvo
GL, Bergeron C,GallegoMelcón S,
Merks JH, Kelsey A,et al.Vinorelbine and
continuous low-dose cyclophosphamide as maintenance
chemotherapy in patients with high-risk rhabdomyosarcoma (RMS
2005): A multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2019;20:1566-75.
11. Pantziarka P,
Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee
A, et al. Next generation metronomic
chemotherapy-report from the Fifth Biennial International
Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016,
Mumbai. Ecancermedicalscience. 2016;10:689.
12. Pramanik R, Agarwala
S, Gupta YK, Thulkar S, Vishnubhatla S, Batra A, et al.
Metronomic chemotherapy vs best supportive care in
progressive pediatric solid malignant tumors: A randomized
clinical trial. JAMA Oncol. 2017;3:1222-7.
13. Pramanik R, Tyagi A,
Agarwala S, Vishnubhatla S, Dhawan D, Bakhshi S. Evaluation of
vascular endothelial growth factor (VEGF) and thrombospondin-1
as bio-markers of metronomic chemotherapy in progressive
pediatric solid malignancies: A randomized study. Indian
Pediatr. 2020;57:508-11.
14. evon-Rivière G, Banavali S, HeississenL, Gomez Garcia W,
Abdolkarimi B, Vaithilingum M, et al. Metronomic
chemotherapy for children in low-and middle-income countries:
survey of current practices and opinions of pediatric
oncologists. J Glob Oncol. 2019;5:1-8.
15. Banavali S, Singh R,
Prasad M, Arora B, Nahar A, Vora T, et al. Is there a
role for a novel maintenance therapy in pediatric patients
with AML? In: 43rd Congress of the International
Society of Paediatric Oncology (SIOP) 2011 Auckland, New
Zealand, 28th-30th october, 2011. Abstract PB015. Pediatr
Blood Cancer. 2011;57:770.
16. Devadas SK, Banavali S.
Retrospective analysis of outcomes of patients with relapsed,
refractory and metastatic sarcomas who have received
metronomic chemotherapy. Gulf J Oncol. 2019;1:22-8.